Palisade Bio, Inc. (PALI)
After hours:
| Previous close | 4.1800 |
| Open | 4.1800 |
| Bid | 3.0600 x 200 |
| Ask | 5.2400 x 200 |
| Day's range | 4.1000 - 4.2800 |
| 52-week range | 3.8200 - 34.3500 |
| Volume | |
| Avg. volume | 255,617 |
| Market cap | 3.994M |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -23.4600 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.75 |
GlobeNewswirePalisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn’s Disease (CD)
- GlobeNewswire
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or th
- GlobeNewswire
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D. Finley, Chief Execut
